TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30763673

Group type: EXPERIMENTAL
Intervention: Exposure therapy (n=25)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR) (n=19)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 44
Study: 27803094

Group type: EXPERIMENTAL
Intervention: Fluconazole (6.5-8.0 mg/kg/d for 28 days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sbv (20 mg/kg/d for 20 days)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sbv
Number of subjects: 53
Study: 26474988

Group type: EXPERIMENTAL
Intervention: Clinic-based individual outpatient rehabilitative exercise during 12 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Community-based group exercise classes during 12 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual medical care (wait-listed control group)
Number of subjects: 240
Study: 24127141

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 812

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: CPAP (≥ 4 h per night on ≥ 70% of nights)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Non-adherent CPAP participants
Number of subjects: 812
Study: 21792663

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 78

Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 78
Study: 21088401

Group type: EXPERIMENTAL
Intervention: Sealing proximal lesions
Number of subjects: 91

Group type: COMPARATOR
Intervention: Flossing instructions (control)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sealing technique
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Participants' behaviour and pain perception
Number of subjects: 91
Study: 17989534

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy
Number of subjects: 0
Study: 15101068

Group type: EXPERIMENTAL
Intervention: Guided self‐help (self‐help manual with a maximum of 18 short weekly visits)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cognitive-behavioral group therapy (CBT) (18 weekly 1.5‐h sessions)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 81
Study: 11594446

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) and Cold exposure
Number of subjects: 9
Study: 9677215

Group type: EXPERIMENTAL
Intervention: Selegiline (alone or in combination with levodopa)
Number of subjects: 12621

Group type: EXPERIMENTAL
Intervention: Selegiline alone
Number of subjects: 12621

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12621
Study: 7803638

Group type: EXPERIMENTAL
Intervention: Cefoxitin plus doxycycline
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Cefotetan plus doxycycline
Number of subjects: 292
Study: 3417081

Group type: EXPERIMENTAL
Intervention: D-xylose test (enteral or parenteral route)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 9
Study: 31469238

Group type: EXPERIMENTAL
Intervention: Tocilizumab at 8 mg/kg/month
Number of subjects: 3080

Group type: COMPARATOR
Intervention: Etanercept at 50 mg/week
Number of subjects: 3080

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 3080
Study: 29072043

Group type: EXPERIMENTAL
Intervention: Active treatment with Mollii® (transcutaneous electrical stimulation)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-active treatment (placebo)
Number of subjects: 31
Study: 27324883

Group type: EXPERIMENTAL
Intervention: Balneotherapy (sulfur bath) combined with home exercise therapy for 3 weeks (15 occasions)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Home exercise therapy alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Balneotherapy (sulfur bath) combined with home exercise therapy
Number of subjects: 41
Study: 23985088

Group type: EXPERIMENTAL
Intervention: Adjunctive emotion regulation group therapy (ERGT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 61
Study: 22829293

Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Number of subjects: 400
Study: 20046519

Group type: COMPARATOR
Intervention: ondansetron 8 mg (group O)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: azasetron 10 mg (group A)
Number of subjects: 98
Study: 19027322

Group type: EXPERIMENTAL
Intervention: ATT+Dzherelo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ATT+Dzherelo+Anemin
Number of subjects: 60

Group type: COMPARATOR
Intervention: ATT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 60
Study: 16163908

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite denture soak
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microwaving
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 12577128

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.4 mg/day for all women, 4 mg/day for women with a previous infant with a neural tube defect)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mandatory fortification of certain foods with folate
Number of subjects: 0
Study: 10577620

Group type: EXPERIMENTAL
Intervention: GnRH agonist (buserelin) 100 microg intranasally once daily for two months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8549037

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1863900

Group type: EXPERIMENTAL
Intervention: Long-term immunotherapy (more than 2 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-term immunotherapy (less than 1 year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-allergic controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy (general)
Number of subjects: 0
Study: 6309461

Group type: EXPERIMENTAL
Intervention: 10 mg enalapril once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 mg enalapril twice daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 23
Study: 31771921

Group type: EXPERIMENTAL
Intervention: Higher protein diet (1.2 g protein/kg BW)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Recommended Daily Allowance level of protein (0.8 g protein/kg BW)
Number of subjects: 80
Study: 29023803

Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF) therapy for 384 weeks
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: HBeAg decline ≥2.2 log10 PEIU/mL at week 24
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: HBeAg decline at week 24
Number of subjects: 266
Study: 26864371

Group type: EXPERIMENTAL
Intervention: Concord grape juice (CGJ) - 12 ounces (355 mL) daily for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo - energy-, taste-, and appearance-matched, daily for 12 weeks
Number of subjects: 25
Study: 25051174

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 21960535

Group type: EXPERIMENTAL
Intervention: Levosimendan (40 μg/kg bolus followed by 0.1/0.2 μg/kg/min continuous infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20621736

Group type: EXPERIMENTAL
Intervention: guaiac-based faecal occult blood test (gFOBT)
Number of subjects: 1984

Group type: EXPERIMENTAL
Intervention: faecal immunochemical test (FIT)
Number of subjects: 1984

Group type: EXPERIMENTAL
Intervention: flexible sigmoidoscopy (FS)
Number of subjects: 1984

Group type: COMPARATOR
Intervention: gFOBT
Number of subjects: 1984

Group type: COMPARATOR
Intervention: FIT
Number of subjects: 1984

Group type: COMPARATOR
Intervention: FS
Number of subjects: 1984
Study: 17641847

Group type: EXPERIMENTAL
Intervention: rhGH 0.2 U/(kg . d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: rhGH 0.4 U/(kg . d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (resting group)
Number of subjects: 45
Study: 15251163

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy followed by completion axillary lymph node dissection (CALND)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy followed by CALND
Number of subjects: 618
Study: 11231941

Group type: EXPERIMENTAL
Intervention: Rofecoxib, 50 mg once daily for 5 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naproxen, 500 mg twice daily for 5 days
Number of subjects: 24
Study: 9685462

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Traditional Care (TC)
Number of subjects: 488
Study: 8614706

Group type: EXPERIMENTAL
Intervention: flesinoxan (5-HT1A agonist)
Number of subjects: 30
Study: 2670798

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation technique (TM)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PR)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cognitive‐behavioral strategies (C)
Number of subjects: 83
Study: 1002852

Group type: EXPERIMENTAL
Intervention: Therapy for /s/‐defective children, 1 hour per week for 5 weeks.
Number of subjects: 10

Group type: COMPARATOR
Intervention: No therapy (control group).
Number of subjects: 10
Study: 29471855

Group type: EXPERIMENTAL
Intervention: 16 sessions of eye movement desensitization and reprocessing (EMDR) therapy preceded by a stabilization phase (8 sessions of Skills Training in Affect and Interpersonal Regulation (STAIR))
Number of subjects: 122

Group type: COMPARATOR
Intervention: 16 sessions of EMDR therapy
Number of subjects: 122
Study: 26656770

Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Test (PASAT) during airway management tasks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Airway management tasks without PASAT
Number of subjects: 150
Study: 24637663

Group type: EXPERIMENTAL
Intervention: Chronic menthol capsule treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 8
Study: 23123230

Group type: EXPERIMENTAL
Intervention: Flurizan (a γ‐secretase modulator)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HBCP analysis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Original ADAS‐Cog analysis
Number of subjects: 14
Study: 19626632

Group type: EXPERIMENTAL
Intervention: (11)C-tyrosine PET
Number of subjects: 27

Group type: COMPARATOR
Intervention: (18)F-FDG PET
Number of subjects: 27
Study: 19105409

Group type: EXPERIMENTAL
Intervention: Mildronate (1 g/day) with basic anti‐diabetic treatment and alpha‐lipoic acid for 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group received basic anti‐diabetic treatment and alpha‐lipoic acid without mildronate
Number of subjects: 70
Study: 15355135

Group type: EXPERIMENTAL
Intervention: ATRIUM model (attention to rules and instances in a unified model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exemplar model (attentional learning covering map)
Number of subjects: 0
Study: 12066703

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (GIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (RM-GIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compomer (Comp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Composite resin (CR)
Number of subjects: 0
Study: 9434659

Group type: EXPERIMENTAL
Intervention: Oxybutynin hydrochloride (5 and 10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8983936

Group type: EXPERIMENTAL
Intervention: New tablet formulation of carbamazepine (400 mg single oral dose)
Number of subjects: 9
Study: 2675433

Group type: EXPERIMENTAL
Intervention: Lamicel (3 mm rod introduced four hours prior to abortion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamicel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lamicel and Control
Number of subjects: 30
Study: 1101046

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 31337743

Group type: EXPERIMENTAL
Intervention: Diaphragmatic release technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thoracic lymphatic pump technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional respiratory retraining
Number of subjects: 60
Study: 27687820

Group type: EXPERIMENTAL
Intervention: Solifenacin (5mg, titrated to optimum dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26041365

Group type: EXPERIMENTAL
Intervention: Patterned feeding experience
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual feeding care experience
Number of subjects: 120
Study: 23582415

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin and lidocaine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 86
Study: 27678225

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouth rinse
Number of subjects: 50

Group type: COMPARATOR
Intervention: Magnetized water (72 hours of magnetization) rinsing for 3 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Magnetized water (24 hours of magnetization) rinsing for 1 minute
Number of subjects: 50

Group type: COMPARATOR
Intervention: Magnetized water (24 hours of magnetization) rinsing for 3 minutes
Number of subjects: 50
Study: 19696808

Group type: EXPERIMENTAL
Intervention: Panoramic radiography
Number of subjects: 84
Study: 16451859

Group type: EXPERIMENTAL
Intervention: Bathers (exposed to water with levels above NOAELs)
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Swallowing water (as part of bathing)
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Water quality standards based on NOAELs
Number of subjects: 2196

Group type: COMPARATOR
Intervention: Current WHO recommendations
Number of subjects: 2196
Study: 14738830

Group type: EXPERIMENTAL
Intervention: Whitening gel containing 6% hydrogen peroxide
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard fluoride toothpaste
Number of subjects: 117
Study: 11404532

Group type: EXPERIMENTAL
Intervention: Triple drug therapy (zidovudine 300 mg or 200 mg for body weight <60 kg, lamivudine 150 mg, didanosine 200 mg or 125 mg for body weight <60 kg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Double drug therapy (zidovudine plus lamivudine)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Triple drug therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Double drug therapy
Number of subjects: 106
Study: 9404926

Group type: EXPERIMENTAL
Intervention: Low-dose G-CSF (50 microg/m2/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-dose G-CSF (5 microg/kg/day, approximately 200 microg/m2/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-dose G-CSF (5 microg/kg/day)
Number of subjects: 30
Study: 8424379

Group type: EXPERIMENTAL
Intervention: Severe energy restriction (SER)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moderate energy restriction (MER)
Number of subjects: 30
Study: 3307498

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study: 31269801

Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention (RRI) delivered over 12 weeks focusing on communication, problem-solving, and negotiation skills.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention during the initial 12 weeks).
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups assessed at baseline, three and six months after the intervention.
Number of subjects: 30
Study: 29929773

Group type: EXPERIMENTAL
Intervention: TAU augmented with TCT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 46
Study: 27608342

Group type: EXPERIMENTAL
Intervention: Size 2 FLMA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Size 2.5 FLMA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Size 2.5 FLMA in children 16-20 kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Size 2 FLMA in children 16-20 kg
Number of subjects: 120
Study: 24513849

Group type: EXPERIMENTAL
Intervention: 1.4 g XOS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2.8 g XOS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22809107

Group type: EXPERIMENTAL
Intervention: Bright light therapy (2,500 Lux) for 1 week
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (50 lux) for 1 week
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bright light therapy (2,500 Lux)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (50 lux)
Number of subjects: 28
Study: 21094366

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg
Number of subjects: 1763
Study: 18500187

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg in 10 mL 0.9% normal saline
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bupivacaine 10 mL of 0.25%
Number of subjects: 43
Study: 15738924

Group type: EXPERIMENTAL
Intervention: MR perfusion measurements using a double-echo FLASH sequence with correction approaches (separating the shortening of T1 and T2*, arterial input function (AIF), and tumor shunts)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Deconvolution from the AIF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Consideration of the AIF
Number of subjects: 18
Study: 11704073

Group type: EXPERIMENTAL
Intervention: Single dose of hydrocortisone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Long-term corticosteroid treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 9218072

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.d.s.
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg b.d.
Number of subjects: 407
Study: 7958669

Group type: EXPERIMENTAL
Intervention: Complete amino acid solution containing the dipeptide L‐alanyl‐L‐glutamine (20 g/L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional amino acid solution (1.5 g amino acids.kg‐1.day‐1)
Number of subjects: 12
Study: 3690031

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 50 mg b.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30826660

Group type: EXPERIMENTAL
Intervention: PTGS2 (COX‐2) high expression in BRAF-mutated cases
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: PTGS2 (COX‐2) high expression in BRAF-wild-type cases
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: PTGS2 (COX‐2) expression in CALGB/Alliance 89803 trial
Number of subjects: 1708
Study: 29976567

Group type: EXPERIMENTAL
Intervention: OnTrack (emotion-focused intervention)
Number of subjects: 301

Group type: COMPARATOR
Intervention: KnowIt (educational/behavioral intervention)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: OnTrack
Number of subjects: 301

Group type: COMPARATOR
Intervention: KnowIt
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 301
Study: 27010512

Group type: EXPERIMENTAL
Intervention: Voice Rehabilitation (VR)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no VR)
Number of subjects: 61
Study: 24619624

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreatoduodenectomy (PPPD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subtotal stomach-preserving pancreatoduodenectomy (SSPPD)
Number of subjects: 100
Study: 22704366

Group type: EXPERIMENTAL
Intervention: Regular screening based on serum PSA measurements offered to 36,270 men in the screening arm.
Number of subjects: 76813

Group type: COMPARATOR
Intervention: No screening provided to 40,543 men in the control arm.
Number of subjects: 76813

Group type: EXPERIMENTAL
Intervention: Screening arm (actual screening).
Number of subjects: 76813

Group type: EXPERIMENTAL
Intervention: Intention-to-screen analysis.
Number of subjects: 76813

Group type: EXPERIMENTAL
Intervention: Overall follow-up period analysis.
Number of subjects: 76813

Group type: EXPERIMENTAL
Intervention: Overall risk reduction.
Number of subjects: 76813
Study: 20671376

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 82

Group type: COMPARATOR
Intervention: Other antiplatelet aggregation drugs
Number of subjects: 82
Study: 17437729

Group type: EXPERIMENTAL
Intervention: Higher baseline leukocyte counts
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Baseline leukocyte count (in increments of 1,000)
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Peak creatine phosphokinase
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Preprocedure TIMI grade 0 flow
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Postprocedural TIMI grade 3 flow rates
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Myocardial blush grade 2/3
Number of subjects: 1268
Study: 15896623

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant MVP (mitomycin C, vinblastin and cisplatin) chemotherapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 118
Study: 11283125

Group type: EXPERIMENTAL
Intervention: High-dose intravenous cytarabine (Ara-C) added to high-dose intravenous methotrexate (MTX)
Number of subjects: 653

Group type: COMPARATOR
Intervention: High-dose intravenous methotrexate (MTX) without Ara-C
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methotrexate (MTX) with Ara-C
Number of subjects: 653